Peruvian authorities have declared a 90-day emergency due to a significant increase in Guillain-Barré Syndrome (GBS), a disorder associated with certain vaccines, the Zika virus, COVID-19, and other viruses. The country’s president has allocated $3.2 million to enhance patient care and detection control. Emergency measures include obtaining intravenous immunoglobulin and human albumin. The health emergency covers all 25 regions of Peru, where 182 GBS cases have been reported, with four deaths. GBS is a rare neurological disorder that can range from mild symptoms to severe paralysis. It is not contagious and typically occurs three weeks after an infection. Certain vaccines, such as those for COVID-19 and RSV, have been linked to GBS. The FDA and other agencies have listed GBS as a potential rare symptom of the Johnson & Johnson Janssen COVID-19 vaccine. The benefits of vaccination still outweigh the risks, according to the CDC.